Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3—T4 pancreatic cancer patients treated with preoperative gemcitabine‐based chemoradiotherapy

Abstract

The hENT1 expression in pancreatic adenocarcinoma strongly influences the outcome of preoperative Gem-CRT treatment. This biomarker could become a useful predictor of therapeutic effect for gemcitabine-based therapy in pancreatic cancer patients.